Načítá se...
Hydroxyurea (hydroxycarbamide) for sickle cell disease
BACKGROUND: Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. It is associated with lifelong morbidity and a reduced life expectancy. Hydroxyurea (hydroxycarbamide), an oral chemotherapeutic drug, ameliorates some of the clinical problems of SCD, in particular that of...
Uloženo v:
| Vydáno v: | Cochrane Database Syst Rev |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Ltd
2017
|
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6478259/ https://ncbi.nlm.nih.gov/pubmed/28426137 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD002202.pub2 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|